{"id":"NCT02122471","sponsor":"Bausch Health Americas, Inc.","briefTitle":"12-Week Study of Plecanatide for CIC (The National CIC3 Study)","officialTitle":"A National, Randomized, 12-Week, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Plecanatide (3.0 and 6.0 mg) in Patients With Chronic Idiopathic Constipation","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-04","primaryCompletion":"2015-05","completion":"2015-07","firstPosted":"2014-04-24","resultsPosted":"2019-03-14","lastUpdate":"2019-05-28"},"enrollment":1410,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Idiopathic Constipation"],"interventions":[{"type":"DRUG","name":"Plecanatide","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Plecanatide 3.0 mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Plecanatide 6.0 mg","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to confirm that the investigational medication, plecanatide, is safe and effective in treating chronic idiopathic constipation.","primaryOutcome":{"measure":"Number of Durable Overall CSBM Responders, Mean Replacement Approach","timeFrame":"12-Week Treatment Period","effectByArm":[{"arm":"Placebo","deltaMin":57,"sd":null},{"arm":"Plecanatide 3 mg","deltaMin":88,"sd":null},{"arm":"Plecanatide 6 mg","deltaMin":88,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":8},"locations":{"siteCount":167,"countries":["United States"]},"refs":{"pmids":["35086735","32660770","29147135"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":466},"commonTop":["Diarrhoea","Headache"]}}